7 Interactions found for:
Drug Interactions
Moderate
Hydroxyzine
+ Vyvanse
The following applies to the ingredients: Hydroxyzine and Lisdexamfetamine (found in Vyvanse)
Using lisdexamfetamine together with hydrOXYzine can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and Food Interactions
Moderate
Hydroxyzine
+ Food
The following applies to the ingredients: Hydroxyzine
Alcohol can increase the nervous system side effects of hydrOXYzine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with hydrOXYzine. Do not use more than the recommended dose of hydrOXYzine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Moderate
Vyvanse
+ Food
The following applies to the ingredients: Lisdexamfetamine (found in Vyvanse)
Using lisdexamfetamine together with alcohol can increase the risk of cardiovascular side effects such as increased heart rate, chest pain, or blood pressure changes. You should avoid or limit the use of alcohol while being treated with lisdexamfetamine. Let your doctor know if you experience severe or frequent headaches, chest pain, and/or a fast or pounding heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and Pregnancy Interactions
Major
Hydroxyzine
+ Pregnancy
The following applies to the ingredients: Hydroxyzine
Professional Content
Use is contraindicated.
US FDA pregnancy category: Not Assigned.
Risk Summary: There are limited data available on use of this drug in early pregnancy to inform of a drug-related risk.
Comments:
-Some authorities state that use is contraindicated during early pregnancy.
-This drug crosses the placental barrier, which may lead to higher fetal than maternal concentrations.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Reports in neonates exposed during late pregnancy and/or labor and delivery included central nervous system (CNS) depression, clonic movements, extrapyramidal symptoms, hypotension, movement disorders, neonatal hypoxic conditions, and/or urinary retention.
Animal studies have revealed evidence of fetal abnormalities at doses substantially above the human therapeutic range. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.
References
- "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Atarax (hydroxyzine)." Pfizer U.S. Pharmaceuticals PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Major
Vyvanse
+ Pregnancy
The following applies to the ingredients: Lisdexamfetamine (found in Vyvanse)
Professional Content
Benefit should outweigh risk.
AU TGA pregnancy category: B3
US FDA pregnancy category: C
Comments:
-The active metabolite of this drug, dexamphetamine, crosses the placenta.
-Premature delivery, low birth weight, and other adverse pregnancy outcomes have been seen in infants born to mothers dependent on amphetamines.
-Monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness.
There are no controlled data of this drug in human pregnancy, but there are some available data for amphetamines in pregnant women. Two case control studies of over a thousand patients exposed to amphetamines at different gestational ages did not show an increase in congenital abnormalities. Additionally, animal studies have revealed no effects on embryofetal morphological development and survival, nor on fertility.
AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- Cerner Multum, Inc. "Australian Product Information." O 0
Drug and Breastfeeding Interactions
Major
Hydroxyzine
+ Breastfeeding
The following applies to the ingredients: Hydroxyzine
Professional Content
Use is not recommended, and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Yes (cetirizine [main metabolite]); Unknown (parent drug)
Excreted into animal milk: No data (parent drug)
Comments:
-Some authorities state that use is contraindicated.
-This drug may be excreted into breast milk.
-Serious side effects have been reported in breastfed newborns/infants.
-Some experts state that healthcare providers should consider switching treatment to alternative agents (e.g., desloratadine, fexofenadine, loratadine), especially in breastfed newborn or preterm infants.
References
- "Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals PROD (2001):
- "Product Information. Atarax (hydroxyzine)." Pfizer U.S. Pharmaceuticals PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):
- Briggs GG, Freeman RK. "Drugs in Pregnancy and Lactation." Philadelphia, PA: Wolters Kluwer Health (2015):
Major
Vyvanse
+ Breastfeeding
The following applies to the ingredients: Lisdexamfetamine (found in Vyvanse)
Professional Content
Use should be avoided during breastfeeding.
Excreted into human milk: Yes
Comments:
-This drug is a prodrug of dextroamphetamine. The effect of dextroamphetamine in milk on the neurological development of a breastfed infant has not been well studied.
-Large dosages of this drug might interfere with milk production, especially in women whose lactation is not well established.
-Blood levels of dextroamphetamine in 3 breastfed infants were up to 14% of the maternal plasma level.
-Four breastfed infants whose mothers took an average dose of 18 mg/day of dextroamphetamine had no adverse effects and showed normal progress with weights between the 10th and 75th percentiles.
-In a study of 20 postpartum women, dextroamphetamine reduced serum prolactin by 25% to 32% (7.5 mg IV dose) and 30% to 37% (15 mg IV dose). Another study showed a 20 mg oral dose produced a sustained suppression of serum prolactin by 40%.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc (2007):
- Cerner Multum, Inc. "Australian Product Information." O 0
- United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):
Therapeutic Duplication Warnings
No warnings were found for your selected drugs.Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Switch to: Professional Interactions
| Drug Interaction Classification | |
|---|---|
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication. |
|
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
| Unknown | No interaction information available. |
Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.